SCHEDULE 13G

Amendment No. 1 
OSCIENT PHARMACEUTICALS CORPORATION 
Common Stock 
Cusip #68812R105 


Cusip #68812R105 
Item 1:	Reporting Person - FMR Corp.
Item 4:	Delaware
Item 5:	0 
Item 6:	0 
Item 7:	92,100 
Item 8:	0 
Item 9:	92,100 
Item 11:	0.120% 
Item 12:	    HC


Cusip #68812R105  
Item 1:	Reporting Person - Edward C. Johnson 3d 
Item 4:	United States of America
Item 5:	0 
Item 6:	0 
Item 7:	92,100 
Item 8:	0 
Item 9:	92,100 
Item 11:	0.120% 
Item 12:	IN 




	SCHEDULE 13G - TO BE INCLUDED IN 
STATEMENTS
	FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)




Item 1(a).	Name of Issuer:	

		OSCIENT PHARMACEUTICALS 
CORPORATION 

Item 1(b).	Name of Issuer's Principal Executive Offices:

		1000 Winter Street
		Suite 2200 
		Waltham, Massachusetts  02451
		  

Item 2(a).	Name of Person Filing: 

		FMR Corp.

Item 2(b).	Address or Principal Business Office or, if None, 
Residence:

		82 Devonshire Street, Boston, 
Massachusetts  02109

Item 2(c).	Citizenship:

		Not applicable

Item 2(d).	Title of Class of Securities:

		Common Stock 

Item 2(e).	CUSIP Number:  

		68812R105 

Item 3.	This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) 
and the person filing, FMR Corp., is a parent holding company 
in accordance with Section 240.13d-1(b)(ii)(G).  (Note:  See 
Item 7).

Item 4.	Ownership

	(a)	Amount Beneficially Owned:	92,100 

	(b)	Percent of Class:	0.120% 

	(c)	Number of shares as to which such 
person has:  

	(i)	sole power to vote or to direct 
the vote:	0 

	(ii)	shared power to vote or to 
direct the vote:	0 

	(iii)	sole power to dispose or to 
direct the disposition of:	92,100 

	(iv)	shared power to dispose or to 
direct the disposition of:	0 



Item 5.	Ownership of Five Percent or Less of a Class.

	If this statement is being filed to report the fact that as of the 
date hereof, the reporting person has ceased to be the 
beneficial owner of more than five percent of the class of 
securities, check the following (X).

Item 6.	Ownership of More than Five Percent on Behalf of Another 
Person.

	Not applicable

Item 7.	Identification and Classification of the Subsidiary Which 
Acquired the Security Being Reported on By the Parent 
Holding Company.

	See attached Exhibit A. 

Item 8.	Identification and Classification of Members of 
the Group.

	Not applicable.  See attached Exhibit A. 

Item 9.	Notice of Dissolution of Group.

	Not applicable.

Item 10.	Certification.

	Inasmuch as the reporting persons are no longer the beneficial 
owners of more than five percent of the number of shares 
outstanding, the reporting persons have no further reporting 
obligation under Section 13(d) of the Securities and Exchange 
Commission thereunder, and the reporting persons have no 
obligation to amend this Statement if any material change 
occurs in the facts set forth herein.

Signature

	After reasonable inquiry and to the best of my knowledge and 
belief, I certify that the information set forth in this statement 
is true, complete and correct. 

September 12, 2005 			
Date

/s/Joseph Mari				
Signature

Joseph Mari			
Duly authorized under Power of Attorney
dated September 9, 2005, by Eric D. Roiter by and on behalf 
of FMR Corp. and its direct and indirect subsidiaries


	SCHEDULE 13G - TO BE INCLUDED IN 
STATEMENTS
	FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)



	Pursuant to the instructions in Item 7 of Schedule 13G, 
Fidelity Management & Research Company ("Fidelity"), 82 
Devonshire Street, Boston, Massachusetts 02109, a wholly-
owned subsidiary of FMR Corp. and an investment adviser 
registered under Section 203 of the Investment Advisers Act 
of 1940, is the beneficial owner of 92,100 shares or 0.120% of 
the Common Stock outstanding of OSCIENT 
PHARMACEUTICALS CORPORATION  ("the Company") 
as a result of acting as investment adviser to various 
investment companies registered under Section 8 of the 
Investment Company Act of 1940.

	Edward C. Johnson 3d and FMR Corp., through its 
control of Fidelity, and the funds each has sole power to 
dispose of the 92,100 shares owned by the Funds.

	Members of the family of Edward C. Johnson 3d, 
Chairman of FMR Corp., are the predominant owners, directly 
or through trusts, of Series B shares of common stock of FMR 
Corp., representing 49% of the voting power of FMR Corp.  
The Johnson family group and all other Series B shareholders 
have entered into a shareholders' voting agreement under 
which all Series B shares will be voted in accordance with the 
majority vote of Series B shares.  Accordingly, through their 
ownership of voting common stock and the execution of the 
shareholders' voting agreement, members of the Johnson 
family may be deemed, under the Investment Company Act of 
1940, to form a controlling group with respect to FMR Corp.

	Neither FMR Corp. nor Edward C. Johnson 3d, 
Chairman of FMR Corp., has the sole power to vote or direct 
the voting of the shares owned directly by the Fidelity Funds, 
which power resides with the Funds' Boards of Trustees.  
Fidelity carries out the voting of the shares under written 
guidelines established by the Funds' Boards of Trustees.



	SCHEDULE 13G - TO BE INCLUDED IN 
STATEMENTS
	FILED PURSUANT TO RULE 13d-1(b) or 13d-2(b)
	RULE 13d-1(f)(1)  AGREEMENT

	The undersigned persons, on September 12, 2005, 
agree and consent to the joint filing on their behalf of this 
Schedule 13G in connection with their beneficial ownership of 
the Common Stock of OSCIENT PHARMACEUTICALS 
CORPORATION at August 31, 2005.

	FMR Corp.

	By /s/ Joseph Mari			
	Joseph Mari
	Duly authorized under Power of Attorney dated 
September 9, 2005, by Eric D. Roiter by and on behalf of 
FMR Corp. and its direct and indirect subsidiaries

	Edward C. Johnson 3d

	By /s/ Joseph Mari			
	Joseph Mari
	Duly authorized under Power of Attorney dated 
September 9, 2005, by Eric D. Roiter by and on behalf of 
Edward C. Johnson 3d

	Fidelity Management & Research Company

	By /s/ Joseph Mari			
	Joseph Mari
	Duly authorized under Power of Attorney dated 
September 9, 2005, by Eric D. Roiter Secretary